{"id":"NCT00528372","sponsor":"AstraZeneca","briefTitle":"A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-02","completion":"2010-07","firstPosted":"2007-09-12","resultsPosted":"2014-05-14","lastUpdate":"2015-10-20"},"enrollment":1067,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Dapagliflozin placebo","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":["Tablets, 500-2000 mg, orally as needed in any arm for rescue, based on protocol specific criteria"]}],"arms":[{"label":"Group 1: Dapagliflozin, 2.5 mg AM","type":"EXPERIMENTAL"},{"label":"Group 1: Dapagliflozin, 10 mg AM","type":"EXPERIMENTAL"},{"label":"Group 1: Dapagliflozin 2.5 mg PM","type":"EXPERIMENTAL"},{"label":"Group 1: Dapagliflozin, 5 mg PM","type":"EXPERIMENTAL"},{"label":"Group 1: Dapagliflozin, 10 mg PM","type":"EXPERIMENTAL"},{"label":"Group 2: Dapagliflozin, 5 mg AM","type":"EXPERIMENTAL"},{"label":"Group 2: Dapagliflozin, 10 mg AM","type":"EXPERIMENTAL"},{"label":"Group 1: Dapagliflozin placebo AM & PM","type":"EXPERIMENTAL"},{"label":"Group 1: Dapaglifozon, 5 mg AM","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking medication for less than 24 weeks since their original diabetes diagnosis. The safety of this treatment will also be studied.","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1","timeFrame":"Baseline to Week 24 (end of Short-term Period)","effectByArm":[{"arm":"Group 1: Dapagliflozin Placebo AM & PM","deltaMin":-0.23,"sd":0.1044},{"arm":"Group 1: Dapagliflozin, 2.5 mg AM","deltaMin":-0.58,"sd":0.1107},{"arm":"Group 1: Dapagliflozin, 5 mg AM","deltaMin":-0.77,"sd":0.1134},{"arm":"Group 1: Dapagliflozin, 10 mg AM","deltaMin":-0.89,"sd":0.1099},{"arm":"Group 1: Dapagliflozin, 2.5 mg PM","deltaMin":-0.83,"sd":0.1125},{"arm":"Group 1: Dapagliflozin, 5 mg PM","deltaMin":-0.79,"sd":0.1117},{"arm":"Group 1: Dapagliflozin, 10 mg PM","deltaMin":-0.79,"sd":0.1037}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0207"},{"comp":"OG000 vs OG002","p":"0.0005"},{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG000 vs OG004","p":null},{"comp":"OG000 vs OG005","p":null},{"comp":"OG000 vs OG006","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":30},"locations":{"siteCount":78,"countries":["United States","Canada","Mexico","Russia"]},"refs":{"pmids":["20566676","25381876","38770818","27461213","26894924"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3672&filename=MB102013_Clinical_Study_Protocol_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":75},"commonTop":["Nasopharyngitis","Headache","Arthralgia","Diarrhoea","Influenza"]}}